MicroRNA-128 acts as a suppressor in the progression of gastrointestinal stromal tumor by targeting B-lymphoma Mo-MLV insertion region 1

• Jinbao Wu ^[1] ; Changjuan Wang ^[1] ; Xia Cui ^[1] ; Lin Liu ^[1] ; Lu Wang ^[1] ; Jing Wang ^[1] ; Xiaohui Xue ^[1] ; Tong Dang ^[1]
  1. [1] Inner Mongolia Institute of Digestive Diseases, The Second Afliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, People’s Republic of China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 2, 2024, págs. 363-374
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction The critical role of microRNA-128 (miR-128) in gastrointestinal-related diseases has been documented. In the current study, we tried to clarify the specific role miR-128 in gastrointestinal stromal tumor (GIST) and the underlying mechanism.

    Methods Differentially expressed genes in GIST were identified following bioinformatics analysis. Then, expression patterns of miR-128 and B-lymphoma Mo-MLV insertion region 1 (BMI-1) in clinical tissue samples and cell lines were characterized, followed by validation of their correlation. GIST-T1 cells were selected and transfected with different mimic, inhibitor, or siRNA plasmids, after which the biological functions were assayed.

    Results We identified low miR-128 and high BMI-1 expression in GIST tissues of 78 patients and 4 GIST cell lines. Ectopic expression of miR-128 or silencing of BMI-1 suppressed the malignant potentials of GIST-T1 cells. As a target of miR-128, BMI-1 re-expression could partly counteract the suppressive effect of miR-128 on the malignancy of GIST-T1 cells.

    Conclusion Our study provided evidence that miR-128-mediated silencing of BMI-1 could prevent malignant progression of GIST, highlighting a promising anti-tumor target for combating GIST.